mFOLFOX6-bevacizumab — Competitive Intelligence Brief

mFOLFOX6-bevacizumab (mFOLFOX6-bevacizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy regimen. Area: Oncology.

phase 3 chemotherapy regimen VEGF Oncology Biologic

Target snapshot

mFOLFOX6-bevacizumab (mFOLFOX6-bevacizumab) — GERCOR - Multidisciplinary Oncology Cooperative Group. mFOLFOX6-bevacizumab is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin with bevacizumab, an anti-angiogenic monoclonal antibody.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
mFOLFOX6-bevacizumab TARGET	mFOLFOX6-bevacizumab	GERCOR - Multidisciplinary Oncology Cooperative Group	phase 3	chemotherapy regimen	VEGF
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
PAZOPANIB HYDROCHLORIDE	PAZOPANIB HYDROCHLORIDE		marketed		VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
Sutent	Sunitinib Malate	Pfizer	marketed	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy regimen class)

1. University Hospital, Grenoble · 2 drugs in this class
2. Canadian Cancer Trials Group · 1 drug in this class
3. Centre Georges Francois Leclerc · 1 drug in this class
4. Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 drug in this class
5. French Innovative Leukemia Organisation · 1 drug in this class
6. AIO-Studien-gGmbH · 1 drug in this class
7. GlaxoSmithKline · 1 drug in this class
8. National Research Center for Hematology, Russia · 1 drug in this class
9. Ospedale Santa Croce-Carle Cuneo · 1 drug in this class
10. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class